|
EIF2AK3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.10820000030077E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.60809999996781E-06 |
| Normal-vs-Stage2 |
2.641800E-04 |
| Normal-vs-Stage3 |
3.86880000258216E-08 |
| Normal-vs-Stage4 |
6.75090000012979E-07 |
| Stage1-vs-Stage2 |
2.912000E-01 |
| Stage1-vs-Stage3 |
4.180500E-03 |
| Stage1-vs-Stage4 |
1.105760E-01 |
| Stage2-vs-Stage3 |
7.821100E-03 |
| Stage2-vs-Stage4 |
5.694300E-02 |
| Stage3-vs-Stage4 |
8.558200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.52589999974562E-07 |
| Normal-vs-AfricanAmerican |
3.207200E-04 |
| Normal-vs-Asian |
1.71407999999262E-05 |
| Caucasian-vs-AfricanAmerican |
4.650000E-01 |
| Caucasian-vs-Asian |
9.140400E-01 |
| AfricanAmerican-vs-Asian |
6.733800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.30780000051622E-07 |
| Normal-vs-Female |
1.99069999995416E-06 |
| Male-vs-Female |
4.355600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.11649999998431E-06 |
| Normal-vs-Age(41-60Yrs) |
3.01839999994336E-07 |
| Normal-vs-Age(61-80Yrs) |
1.7617999999997E-06 |
| Normal-vs-Age(81-100Yrs) |
6.666200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.102570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.263600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.809600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.361600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.247600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.056600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.7016999999977E-05 |
| Classical-VS-Follicular |
7.764000E-03 |
| Classical-VS-Other |
2.514000E-01 |
| Classical-VS-Normal |
6.55090000023506E-07 |
| Tall-VS-Follicular |
9.70570000036197E-07 |
| Tall-VS-Other |
7.053000E-01 |
| Tall-VS-Normal |
1.18599996490332E-09 |
| Follicular-VS-Other |
1.221200E-01 |
| Follicular-VS-Normal |
1.664880E-03 |
| Other-VS-Normal |
7.90040000000491E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.04320000005043E-06 |
| Normal-vs-N1 |
2.24630000156267E-08 |
| N0-vs-N1 |
4.174200E-02 |
|
|
